Certara Products - Simcyp Archives | Page 2 of 21

On-Demand Webinar

Simcyp Version 24: Advancing PBPK capabilities and translating new science and technology into regulatory-accepted predictive modeling

With the release of Version 24, the Simcyp Simulator introduces cutting-edge enhancements that further elevate…

CertaraFebruary 7, 2025

Publication

Static Versus Dynamic Model Predictions of Competitive Inhibitory Metabolic Drug–Drug Interactions via Cytochromes P450: One Step Forward and Two Steps Backwards

Predicting metabolic drug–drug interactions (DDIs) via cytochrome P450 enzymes (CYP) is essential in drug development,…

CertaraDecember 12, 2024

Publication

Real-world application of physiologically based pharmacokinetic models in drug discovery

The utility of physiologically based pharmacokinetic (PBPK) models in support of drug development has been…

CertaraNovember 22, 2024

Publication

Recent applications of pharmacometrics and systems pharmacology approaches to improve and optimize drug therapy for pregnant and lactating women

The article "Recent Applications of Pharmacometrics and Systems Pharmacology Approaches to Improve and Optimize Drug…

CertaraNovember 18, 2024

Video

Simcyp™ PBPK Simulator | Predicting Drug Performance

CertaraSeptember 26, 2024

eBook

Waiving clinical studies & accelerating drug development for kinase inhibitor drugs

Whether you're in pre, early, or late clinical stages, this eBook offers real-world insights into…

CertaraAugust 28, 2024

eBook

PBPK Applications (MIFD) Using the Simcyp™ Simulator

Explores strategies, regulatory validation, and solutions in small-molecule human Physiologically Based Pharmacokinetic modeling (PBPK).

CertaraAugust 28, 2024

Case Study

Asciminib – PBPK Modeling Streamlines Development and Avoids Over 10 Clinical Trials

Asciminib (Scemblix®) is a novel drug with a unique mechanism of action for treating CML.…

CertaraAugust 27, 2024

Publication

Prediction of CYP-mediated DDIs involving inhibition: Approaches to address the requirements for system qualification of the Simcyp Simulator

The article "Prediction of CYP-mediated DDIs involving inhibition: Approaches to address the requirements for system…

CertaraAugust 26, 2024

Publication

A guide to developing population files for physiologically-based pharmacokinetic modeling in the Simcyp Simulator

This collaborative effort by Certara and the Centre for Applied Pharmacokinetic Research (CAPKR) at The…

CertaraJuly 24, 2024

Certara Products – Simcyp

Simcyp Version 24: Advancing PBPK capabilities and translating new science and technology into regulatory-accepted predictive modeling

Static Versus Dynamic Model Predictions of Competitive Inhibitory Metabolic Drug–Drug Interactions via Cytochromes P450: One Step Forward and Two Steps Backwards

Real-world application of physiologically based pharmacokinetic models in drug discovery

Recent applications of pharmacometrics and systems pharmacology approaches to improve and optimize drug therapy for pregnant and lactating women

Simcyp™ PBPK Simulator | Predicting Drug Performance

Waiving clinical studies & accelerating drug development for kinase inhibitor drugs

PBPK Applications (MIFD) Using the Simcyp™ Simulator

Asciminib – PBPK Modeling Streamlines Development and Avoids Over 10 Clinical Trials

Prediction of CYP-mediated DDIs involving inhibition: Approaches to address the requirements for system qualification of the Simcyp Simulator

A guide to developing population files for physiologically-based pharmacokinetic modeling in the Simcyp Simulator

Newsletter sign up

Quick links

Solutions

Contact